NOVO NORDISK – Rybelsus (Semaglutide) – 3 mg Tablets
Supplied in a box containing 10 x 3 mg oral tablets.
Active Ingredient: Semaglutide.
Indications:
Rybelsus is prescribed for adults with type 2 diabetes to improve blood sugar control, especially when diet and exercise alone are not sufficient. It may also assist in weight management as part of a diabetes treatment regimen.
Administration:
Taken orally once daily, Rybelsus should be administered on an empty stomach, at least 30 minutes before the first food, drink, or other medication of the day, with up to 4 ounces of water. Treatment usually starts at 3 mg daily, with dosage adjustments based on therapeutic goals as directed by a healthcare provider.
Effects:
As a GLP-1 receptor agonist, Rybelsus works by mimicking the effects of GLP-1 to increase insulin secretion, decrease glucagon release, and slow gastric emptying, leading to improved blood sugar control and appetite reduction.
Side Effects:
Common side effects include nausea, stomach discomfort, and decreased appetite. Less common but serious side effects may include pancreatitis, kidney issues, and severe gastrointestinal symptoms.
Contraindications:
Not suitable for individuals with a history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disorders. Regular monitoring of blood sugar and health markers is recommended to optimize treatment.